ATE254458T1 - Antibiotische zusammensetzungen zur behandlung des auges - Google Patents

Antibiotische zusammensetzungen zur behandlung des auges

Info

Publication number
ATE254458T1
ATE254458T1 AT99956504T AT99956504T ATE254458T1 AT E254458 T1 ATE254458 T1 AT E254458T1 AT 99956504 T AT99956504 T AT 99956504T AT 99956504 T AT99956504 T AT 99956504T AT E254458 T1 ATE254458 T1 AT E254458T1
Authority
AT
Austria
Prior art keywords
eye
treating
antibiotic compositions
antibiotic
compositions
Prior art date
Application number
AT99956504T
Other languages
English (en)
Inventor
Gerald Cagle
Robert L Abshire
David W Stroman
John M Yanni
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26799441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE254458(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Inc filed Critical Alcon Inc
Application granted granted Critical
Publication of ATE254458T1 publication Critical patent/ATE254458T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT99956504T 1998-09-30 1999-09-29 Antibiotische zusammensetzungen zur behandlung des auges ATE254458T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10250698P 1998-09-30 1998-09-30
US10250498P 1998-09-30 1998-09-30
PCT/US1999/022622 WO2000018386A2 (en) 1998-09-30 1999-09-29 Antibiotic compositions for treatment of the eye, ear and nose

Publications (1)

Publication Number Publication Date
ATE254458T1 true ATE254458T1 (de) 2003-12-15

Family

ID=26799441

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99956504T ATE254458T1 (de) 1998-09-30 1999-09-29 Antibiotische zusammensetzungen zur behandlung des auges
AT03020587T ATE501732T1 (de) 1998-09-30 1999-09-29 Antibiotische zusammensetzung, die moxifloxacin enthält, zur behandlung von augen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT03020587T ATE501732T1 (de) 1998-09-30 1999-09-29 Antibiotische zusammensetzung, die moxifloxacin enthält, zur behandlung von augen

Country Status (18)

Country Link
EP (5) EP1117401B1 (de)
JP (5) JP2002525317A (de)
KR (1) KR101463243B1 (de)
CN (2) CN1184968C (de)
AR (2) AR020661A1 (de)
AT (2) ATE254458T1 (de)
AU (1) AU762827B2 (de)
BR (1) BRPI9914151B1 (de)
CA (3) CA2342211C (de)
CY (3) CY1111404T1 (de)
DE (2) DE69943287D1 (de)
DK (5) DK2796138T3 (de)
ES (4) ES2526521T3 (de)
HK (1) HK1038691B (de)
PT (5) PT1117401E (de)
TR (2) TR200100883T2 (de)
TW (1) TWI222361B (de)
WO (1) WO2000018386A2 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR020661A1 (es) 1998-09-30 2002-05-22 Alcon Lab Inc Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento
US6716830B2 (en) 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US6509327B1 (en) * 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
DE19937116A1 (de) * 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
DE19937115A1 (de) 1999-08-06 2001-02-08 Bayer Ag Wäßrige Arzneimittelformulierung von Moxifloxacin oder Salzen davon
ES2207549T3 (es) 1999-09-24 2004-06-01 Alcon Inc. Formulaciones en suspension topicas que contienen ciprofloxacino y desametasona.
DE19962470A1 (de) * 1999-12-22 2001-07-12 Schulz Hans Herrmann Verwendung von Chemotherapeutika
AU2001261748A1 (en) * 2000-05-19 2001-12-03 Alcon Laboratories Inc. Antibiotic compositions for treatment of the eye, ear and nose
CA2412575C (en) 2000-07-26 2009-12-29 Onkar N. Singh Improved process for manufacturing compositions containing ciprofloxacin and hydrocortisone
JPWO2002040028A1 (ja) * 2000-11-16 2004-03-18 わかもと製薬株式会社 抗菌ゲル化点眼剤
WO2002049633A2 (en) 2000-12-20 2002-06-27 Alcon, Inc. Use of amidoamines to treat or prevent acanthamoeba and fungal infections
WO2002049627A2 (en) * 2000-12-20 2002-06-27 Alcon, Inc. Antifungal compositions containing an antibiotic and one or more amidoamines
PL212457B1 (pl) 2001-09-21 2012-10-31 Alcon Zastosowanie kombinacji ciprofloksacyny i deksametazonu
US7220431B2 (en) 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
AU2004272414B2 (en) 2003-09-10 2009-05-28 Kyorin Pharmaceutical Co., Ltd. 7-(4-substituted 3- cyclopropylaminomethyl-1- pyrrolidinyl) quinolonecarboxylic acid derivative
WO2006015545A1 (fr) * 2004-08-11 2006-02-16 Shenzhen Tys R & D Co., Ltd. Capsule de gelatine de moxifloxacin et procede pour sa preparation
WO2006029074A2 (en) * 2004-09-03 2006-03-16 Piedmont Pharmaceuticals, Llc Methods for transmembrane treatment and prevention of otitis media
DE102005055385A1 (de) * 2004-12-09 2006-06-14 Bayer Healthcare Ag Arzneimittel zur hygienischen Applikation im Ohr
MX2007005980A (es) * 2004-12-10 2007-07-10 Alcon Inc Composiciones para el tratamiento de infecciones oticas.
CN101317847B (zh) * 2007-06-06 2010-10-13 深圳市瑞谷医药技术有限公司 一种眼用或耳鼻用药物组合物及其用途
TWI544934B (zh) * 2008-06-09 2016-08-11 愛爾康研究有限公司 含有氟喹諾酮抗生素藥物之經改良藥學組成物
EP2448587B1 (de) * 2009-07-02 2018-08-22 Alcon Research, Ltd. Zusammensetzungen mit finafloxacin und verfahren zur behandlung augen-, ohren oder naseninfektionen
PH12012501371A1 (en) * 2010-01-07 2012-10-22 Novartis Ag Methods and compositions for applying moxifloxacin to the ear
RU2014127492A (ru) 2011-12-06 2016-02-10 Алькон Рисерч, Лтд. Композиции целлюлозного геля с улучшенной стабильностью вязкости
RU2472507C1 (ru) * 2012-02-01 2013-01-20 Закрытое акционерное общество "Брынцалов-А" Водный состав на основе моксифлоксацина для парентерального введения
US9504691B2 (en) 2012-12-06 2016-11-29 Alcon Research, Ltd. Finafloxacin suspension compositions
US20150164882A1 (en) 2013-07-22 2015-06-18 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20160279055A1 (en) 2013-07-22 2016-09-29 Imprimis Pharmaceuticals, Inc. Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
CN104224802B (zh) * 2014-09-19 2017-12-12 南京优科生物医药研究有限公司 一种盐酸莫西沙星滴耳剂及其制备方法
RU2595837C2 (ru) * 2014-09-29 2016-08-27 Открытое Акционерное Общество "Татхимфармпрепараты" Состав и способ получения глазных капель
CN108348516B (zh) * 2015-10-29 2021-02-12 特一华制药株式会社 外用剂
JP2021524861A (ja) * 2018-04-03 2021-09-16 ハイデラバード アイ リサーチ ファウンデーション フルオロキノロン系抗生物質の眼内投与のための粘膜付着性薬物送達システム
IT201900005280A1 (it) * 2019-04-05 2020-10-05 Ntc S R L Composizione otologica
EP4164625A1 (de) * 2020-06-10 2023-04-19 Ocular Science, Inc. Zusammensetzungen und verwendungen in verfahren zur postoperativen augenpflege
CN116270662A (zh) * 2021-12-03 2023-06-23 苏州欧康维视生物科技有限公司 盐酸莫西沙星地塞米松磷酸钠滴眼液
KR102656260B1 (ko) 2022-10-14 2024-04-09 주식회사태준제약 목시플록사신을 포함하는 안과용 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223493A (en) 1984-12-28 1993-06-29 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
CA1325382C (en) * 1988-01-27 1993-12-21 Takahiro Ogawa Locally administrable therapeutic composition for inflammatory disease
DE3906365A1 (de) * 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
WO1990001933A1 (en) * 1988-08-26 1990-03-08 Alcon Laboratories, Inc. Combination of quinolone antibiotics and steroids for topical ophthalmic use
JPH03109236A (ja) * 1989-09-22 1991-05-09 Hoya Corp 半導体超微粒子分散ガラスの製造方法
JPH085779B2 (ja) * 1989-09-22 1996-01-24 杏林製薬株式会社 フレロキサシン点眼液
TW209865B (de) * 1992-01-10 1993-07-21 Bayer Ag
ATE300936T1 (de) 1992-05-06 2005-08-15 Alcon Lab Inc Anwendung von boral-polyol-komplexen für ophthalmische arzneizusammensetzungen
DE4424369A1 (de) * 1994-07-11 1996-01-18 Bayer Ag Pyrido[3,2,1.i,j][3,1]benzoxazinderivate
JPH0892241A (ja) * 1994-09-22 1996-04-09 Ss Pharmaceut Co Ltd ５−ヒドラジノキノロンカルボン酸誘導体及びこれを有効成分とする抗菌剤
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
MX9701731A (es) * 1995-06-06 1997-10-31 Bayer Ag Composiciones anti-bacterianas oticas, no-irritantes, no-sensibles y no-toxicas para el oido.
JP3290914B2 (ja) * 1997-03-17 2002-06-10 参天製薬株式会社 眼組織におけるキノロン系抗菌剤の定量装置
SI1017392T1 (en) * 1997-09-25 2002-12-31 Bayer Aktiengesellschaft Medicament formulation with a controlled release of an active agent
EP1115373B1 (de) 1998-09-23 2004-12-22 Unilever N.V. Orale zusammensetzung mit verbessertem bleichendem effekt
AR020661A1 (es) 1998-09-30 2002-05-22 Alcon Lab Inc Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento
KR20010107754A (ko) * 2000-05-26 2001-12-07 민경윤 경구투여용 속용정의 제조 방법

Also Published As

Publication number Publication date
HK1038691B (en) 2004-04-23
CY1115759T1 (el) 2017-01-25
EP1117401A2 (de) 2001-07-25
ES2519190T3 (es) 2014-11-06
EP2796138A1 (de) 2014-10-29
EP1384478B1 (de) 2011-03-16
ES2207307T3 (es) 2004-05-16
DK2269602T3 (en) 2014-12-15
KR20010075138A (ko) 2001-08-09
TWI222361B (en) 2004-10-21
DK2301541T3 (da) 2014-09-01
ATE501732T1 (de) 2011-04-15
BRPI9914151B8 (de) 2021-05-25
PT2796138T (pt) 2016-09-22
EP1117401B1 (de) 2003-11-19
AR020661A1 (es) 2002-05-22
HK1150769A1 (en) 2012-01-13
PT1117401E (pt) 2004-03-31
JP2013018799A (ja) 2013-01-31
AU1310100A (en) 2000-04-17
PT2301541E (pt) 2014-10-29
TR200704370T2 (tr) 2007-11-21
PT1384478E (pt) 2011-05-12
CN100374114C (zh) 2008-03-12
CY1111404T1 (el) 2015-08-05
DK2796138T3 (en) 2016-12-05
HK1038691A1 (en) 2002-03-28
HK1059572A1 (en) 2004-07-09
EP2301541A1 (de) 2011-03-30
DK1384478T3 (da) 2011-05-23
CN1184968C (zh) 2005-01-19
CA2659064A1 (en) 2000-04-06
JP2009007375A (ja) 2009-01-15
DK1117401T3 (da) 2004-02-23
JP2012067141A (ja) 2012-04-05
AU762827B2 (en) 2003-07-03
WO2000018386A3 (en) 2000-06-08
AR081393A2 (es) 2012-08-29
BR9914151A (pt) 2001-06-26
CY1115916T1 (el) 2017-01-25
ES2526521T3 (es) 2015-01-13
EP2796138B1 (de) 2016-08-17
WO2000018386A2 (en) 2000-04-06
ES2602956T3 (es) 2017-02-23
TR200100883T2 (tr) 2001-10-22
DE69943287D1 (de) 2011-04-28
CA2342211A1 (en) 2000-04-06
EP1384478A1 (de) 2004-01-28
EP2269602A1 (de) 2011-01-05
CA2774207A1 (en) 2000-04-06
DE69912972D1 (de) 2003-12-24
EP2301541B1 (de) 2014-08-20
KR101463243B1 (ko) 2014-12-17
BRPI9914151B1 (pt) 2017-10-03
PT2269602E (pt) 2014-12-29
CN1650863A (zh) 2005-08-10
DE69912972T2 (de) 2004-04-22
JP5563041B2 (ja) 2014-07-30
HK1150756A1 (en) 2012-01-13
EP2269602B1 (de) 2014-11-19
JP2002525317A (ja) 2002-08-13
CN1320035A (zh) 2001-10-31
CA2342211C (en) 2009-05-26
JP2014144982A (ja) 2014-08-14

Similar Documents

Publication Publication Date Title
DE69912972D1 (de) Antibiotische zusammensetzungen zur behandlung des auges
DE69819786D1 (de) Biozidzusammensetzungen zur behandlung vom wasser
DE69928542D1 (de) 5ht2-agoniste zur behandlung des glaukoms
AU4025599A (en) Compositions comprising anti-microtubule agents for treating or preventing inflammatory diseases
ATE329911T1 (de) Fsh mimetika zur behandlung von infertilität
DE69936890D1 (de) Vorrichtung zur Behandlung von Ischämie
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60011570D1 (de) Arylpiperazinyl-cyclohexyl indolderivate zur behandlung von depressionen
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
DK1130968T3 (da) Pesticid sammensætning til frøbehandling
DE69323303D1 (de) Zusammensetzungen zur Behandlung des trockenen Auges
DE69603089D1 (de) Zusammensetzung zur behandlung von mauerwerk
ATE326842T1 (de) Zusammensetzung zur saatgutbehandlung
ATE263777T1 (de) Zusammensetzungen zur behandlung von entzündungsreaktionen
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE69941821D1 (de) Fluorenthaltende zusammensetzung zur behandlung von oberflächen
DE69905214D1 (de) Mittel zur Behandlung der Osteoporose
DE69913380D1 (de) Zusammensetzung zur behandlung von periodontalen erkrankungen
DE60001255D1 (de) Zusammensetzung zur Behandlung von Polyesterfaser
DE60021252D1 (de) Antikonvulsiva zur behandlung von autismus
DE69904849D1 (de) 3-tetrahydropyridin-4-yl-indole zur behandlung von psychotischen störungen
PT1100329E (pt) Composicoes aquosas reguladoras do crescimento
ATE274044T1 (de) Zusammensetzungen zur behandlung von gewebe
EP1096927A4 (de) Zusammensetzung für stressbehandlung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1117401

Country of ref document: EP

RZN Patent revoked